Crossmark Global Holdings’s Protagonist Therapeutics PTGX Stock Holding History

Crossmark Global Holdings’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$415K	Sell	3,389 -100	-3%	-$10.4K	0.01%	934
2026 Q1	$368K	Sell	3,489 -471	-12%	-$41.7K	0.01%	939
2025 Q4	$346K	Sell	3,960 -6	-0.2%	-$491	0.01%	968
2025 Q3	$263K	Sell	3,966 -99	-2%	-$5.63K	﹤0.01%	1150
2025 Q2	$225K	Buy	+4,065	New	+$195K	﹤0.01%	1219

Other funds holding PTGX

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Cache Advisors San Francisco, California $1.18B AUM 44.04% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

Crossmark Global Holdings's PTGX Position: Q2 2026 in Review

Crossmark Global Holdings reduced its Protagonist Therapeutics (PTGX) stake by 2.9% in Q2 2026, selling an estimated $10.4K and leaving 3,389 shares worth $415K. The position accounts for 0.01% of the portfolio, ranked #934.

Crossmark Global Holdings first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 31 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Crossmark Global Holdings held 3,389 shares of Protagonist Therapeutics worth $415K as of Q2 2026.
Crossmark Global Holdings sold 100 Protagonist Therapeutics shares in Q2 2026, an estimated $10.4K.
Protagonist Therapeutics made up 0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #934 holding.
Crossmark Global Holdings first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
31 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.